Altesa BioSciences key facts
as of Oct 2026- Developer of antiviral medicines designed for the treatment of respiratory infections and global viral threats.
- Altesa BioSciences is valued at approximately $190.0M as of Oct 2026, set at its later-stage round, Feb 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $114.0M across 2 recorded rounds; the latest was Later Stage VC ($75.0M) in Feb 2026.
- Notable investors include Pitango Venture Capital, Forbion, Atlantic Partners, GRA Venture Fund, Medicxi — 7 tracked in total.
- Altesa BioSciences has filed 2 Form Ds with the SEC, most recently Jul 2023 ($35.0M sold to 18 investors).
- Status: Privately Held (backing).
Valued at $190.0M at its later-stage round, Feb 2026. Nothing has traded since.
- ·Watch Altesa BioSciences: the Monday email on marks, rounds and moves
Altesa BioSciences funding rounds
2 roundsAltesa BioSciences valuation
Altesa BioSciences was valued at $190 million at its later-stage round in Feb 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Altesa BioSciences raised?
Altesa BioSciences has raised $114 million across 2 recorded rounds since 2022. The largest was a $75 million later-stage round in Feb 2026.
Altesa BioSciences has filed 2 Form Ds with the SEC, most recently in Jul 2023 ($35 million sold to 18 investors).
Altesa BioSciences investors
7 investors are on record for Altesa BioSciences, including Pitango Venture Capital, Forbion, Atlantic Partners and GRA Venture Fund. The later-stage round in Feb 2026 drew 17 investors.
About Altesa BioSciences
Developer of antiviral medicines designed for the treatment of respiratory infections and global viral threats. The company focuses on developing broad-spectrum antiviral drugs, integrating capsid inhibitors with clinical-stage research to address common respiratory viruses, enabling healthcare providers to access effective treatments that mitigate disease progression, improve patient outcomes, and reduce the burden of viral infections through targeted therapeutic interventions and regulatory-approved formulations.
- Sector
- Healthcare
- HQ
- College Park, GA, United States
- Founded
- 2020
- Employees
- 8
- Website
- altesabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.